<DOC>
	<DOCNO>NCT01844505</DOCNO>
	<brief_summary>The purpose study show Nivolumab and/or Nivolumab combination Ipilimumab extend progression free survival overall survival compare Ipilimumab alone .</brief_summary>
	<brief_title>Phase 3 Study Nivolumab Nivolumab Plus Ipilimumab Versus Ipilimumab Alone Previously Untreated Advanced Melanoma ( CheckMate 067 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histologically confirm stage III ( unresectable ) stage IV melanoma Treatment na√Øve patient Measurable disease compute tomography ( CT ) Magnetic Resonance Imaging ( MRI ) per RECIST 1.1 criterion Tumor tissue unresectable metastatic site disease biomarker analyse Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Active brain metastasis leptomeningeal metastasis Ocular melanoma Subjects active , know suspected autoimmune disease Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day treatment Prior treatment antiProgrammed Death receptor1 ( PD1 ) , antiProgrammed Death1 ligand1 ( PDL1 ) , antiPDL2 , anticytotoxic T lymphocyte associate antigen4 ( antiCTLA4 ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>